EYPT – eyepoint pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
5/8
08:07 am
eypt
Low
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its price target lowered by analysts at Robert W. Baird from $46.00 to $38.00. They now have an "outperform" rating on the stock.
5/8
07:08 am
eypt
Low
EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments [Yahoo! Finance]
5/8
07:00 am
eypt
Low
EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments
5/7
09:05 am
eypt
Medium
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its price target lowered by analysts at Chardan Capital from $39.00 to $28.00. They now have a "buy" rating on the stock.
5/7
08:01 am
eypt
Medium
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its price target lowered by analysts at Mizuho from $39.00 to $30.00. They now have a "buy" rating on the stock.
5/8/2024
07:00 am
EYPT
0.5%
MISS
3/7/2024
07:00 am
EYPT
-6.3%
BEAT
11/1/2023
07:00 am
EYPT
14.6%
BEAT
8/2/2023
07:00 am
EYPT
0.3%
MISS
5/8
07:01 am
Maintains
Outperform
Outperform
Baird
Low
0.5%
5/8
07:01 am
Maintains
Outperform
Outperform
Baird
Low
0.5%
5/7
08:48 am
Maintains
Buy
Buy
Chardan Capital
Medium
5.6%
5/7
07:04 am
Maintains
Buy
Buy
Mizuho
Medium
5.0%
5/7
07:04 am
Maintains
Buy
Buy
Mizuho
Medium
5.0%
5/8
04:23 pm
eypt
Low
Form 4 EyePoint Pharmaceuticals For: May 06 Filed by: Cormorant Global Healthcare Master Fund, LP
5/8
07:05 am
eypt
Low
Form 8-K EyePoint Pharmaceuticals For: May 08
5/6
09:26 am
eypt
High
Form 8-K EyePoint Pharmaceuticals For: May 06
5/1
05:09 pm
eypt
High
Form SC 13G/A EyePoint Pharmaceuticals Filed by: Adage Capital Management, L.P.
4/30
08:53 pm
eypt
Low
Form SC 13G EyePoint Pharmaceuticals Filed by: Adage Capital Management, L.P.
Show more
Top News Gainers
1/23 EyePoint Pharmaceuticals Announces Preliminary Fourth Quarter and Full-Year 2019 Revenues 23.6%
4/28 Form 8-K EyePoint Pharmaceuticals For: Apr 22 10.8%
10/17 Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 10.0%
4/6 Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) was downgraded by analysts at B. Riley from a "buy" rating to a "neutral" rating. They now have a $1.00 price target on the stock, down previously from $4.00. 9.3%
10/15 Form 4 EyePoint Pharmaceuticals For: Oct 12 Filed by: Paggiarino Dario A. 8.4%
9/11 Eyepoint +1.9% as Guggenheim starts at Buy [Seeking Alpha] 7.1%
3/13 Form 4 EyePoint Pharmaceuticals For: Mar 12 Filed by: Elston George 7.0%
11/27 Form 8-K EyePoint Pharmaceuticals For: Nov 27 5.5%
8/7 Q2/2019 6/30/2019 EPS -0.110 ZacksConsensus -0.130 ActVsEst 0.020 - Beat 5.1%
11/1 EyePoint Pharmaceuticals Secures New Patient Access Agreement with Vizient Inc. for DEXYCU® 4.9%
Top News Decliners
11/7 Q3/2019 9/30/2019 EPS -0.150 ZacksConsensus -0.140 ActVsEst (0.010) - Miss -31.1%
2/20 EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock -20.8%
7/25 EyePoint Pharmaceuticals Announces Early Assignment of Permanent and Specific J-Code J7314 for YUTIQ® by the Center for Medicare and Medicaid Services (CMS) -16.4%
7/30 EyePoint Pharmaceuticals Presents Positive Data Showcasing YUTIQ® at the 37th Annual Scientific Meeting of the American Society of Retina Specialists -15.2%
11/9 Edited Transcript of EYPT earnings conference call or presentation 7-Nov-19 1:30pm GMT [Yahoo! Finance News] -13.5%
3/16 Form 10-K EyePoint Pharmaceuticals For: Dec 31 -13.1%
11/7 EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] -12.7%
4/1 EyePoint Pharmaceuticals Provides COVID-19 Pandemic Business Operations Update -12.3%
3/5 EyePoint Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Corporate Progress -9.7%
2/4 Form 8-K EyePoint Pharmaceuticals For: Feb 03 -8.5%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3